It should be noted that the in vivo anti-tumor effect was lost when mice were treated with lipofermata and an anti-CD8 depleting antibody or when the therapy was administered in immunodeficient (NOD/SCID) non-obese diabetic–severe mice, indicating that the anti-tumor effect is anyway mediated by T cells rather than neutrophils (110). This evidence concerns the gene CD8A and neoplasm.